Search PubMed⌕ Search

Biomedical subjects

T A Pearson

Publications and source records attributed to T A Pearson.

At least 19 recordsLinked to original sources
PubMed1998

Rural epidemiology: insights from a rural population laboratory.

To study the epidemiology of rural populations in the context of contemporary issues in public health, a population laboratory (Health Census '89) was established in Otsego County, New York, by the Research Institute of the M.I. Bassett Hospital, affiliated with the Columbia University School of Public Health. Such a laboratory is needed because of an apparent lag in positive health indices in rural populations across the United States, resulting in rates of chronic diseases, such as coronary heart disease, for which rural areas now exceed urban ones. This was confirmed for Otsego County by the survey Health Census '89, the foundation of a rural population laboratory, in which all residents were enumerated and characterized as to their prevalent diseases, health behaviors, use of preventive services, and environmental exposures. Heart disease, cancer, and diabetes mellitus rates were found to exceed average rates for US urban areas, while the data on preventive health behaviors suggest this is a population of "late adopters." The survey, conducted in 1989, had an 86.6% response rate, and enumerated 17,147 households and 44,406 persons. The authors discuss adults aged 17-64 years, 58 percent of the total census (n=25,614). Sharp gradients in disease prevalence, risk factors, and utilization of preventive services were observed across educational strata. Data from Health Census '89 were used as the basis for a successful community intervention program, which targeted identified high risk groups. Rural populations are excellent settings for community interventions, offering laboratories where new strategies of risk reduction and provision of preventive services might be tested.

Adolescent↗
PubMed1998

Lipid lowering in a multidisciplinary clinic compared with primary physician management.

A multidisciplinary lipid reduction clinic achieved greater reduction of serum cholesterol when compared with primary physicians among patients with coronary heart disease. The lipid clinic was more likely than the primary physicians to prescribe lipid-lowering medication, to prescribe multiple medications, and to use drug doses in excess of the "starting dose."

Aged↗
PubMed1998

What to consider when conducting a cost-effectiveness analysis in a clinical setting.

More data are needed providing strong evidence that nutrition services are cost-effective. Economic evaluations, such as cost-effectiveness analyses, are excellent practice-based research projects. We conducted a cost-effectiveness analysis in a clinical setting to compare the cost-effectiveness of lipid-lowering medications plus diet therapy (medication + diet) with diet therapy alone (diet alone) for treating patients with hypercholesterolemia. Twenty-five adults with hypercholesterolemia (13 receiving medication + diet, 12 receiving diet alone) either participated in an 8-week, home-based, step 1 intervention or were counseled about diet and lifestyle by their care provider. Diet, cost, and laboratory data were collected at baseline, at 9 months, and at 19 months after participation in the intervention (follow-up). Cost per unit change in outcome was evaluated for each group. The diet-alone group made only small changes in dietary intake, changes that were smaller in magnitude than those made by the medication + diet group. Nevertheless, at 9 months, costs per unit change in total serum cholesterol level and low-density lipoprotein cholesterol (LDL-C) level were approximately $24 and $83 less, respectively, for the diet-alone group. At follow-up, however, the cost per unit change in LDL-C level was approximately $17 less for the medication + diet group, which can be explained by the medication + diet group's greater decrease in LDL-C level. The following elements should be considered when conducting a cost-effectiveness analysis of medical nutrition therapy: effectiveness of the nutrition intervention, adequate sample size, confounding variables, compliance with diet and drug therapy, direct and indirect costs of care, and follow-up evaluation.

Adult↗
PubMed1998

Longitudinal changes in dehydroepiandrosterone concentrations in men and women.

Dehydroepiandrosterone, an adrenal steroid, has many purported roles in the body and has been used as an oral supplement in the treatment of various illnesses. Because little is known about normal changes over time in dehydroepiandrosterone concentrations, we studied the 5-year change in plasma dehydroepiandrosterone concentrations in 614 free-living adults. Two hundred seventy-three males and 341 females had dehydroepiandrosterone and dehydroepiandrosterone sulfate concentrations measured in 1989 and 1994. Demographic data were also obtained. Dehydroepiandrosterone concentrations differed significantly by sex and 5-year age group. The average decline in dehydroepiandrosterone was 5.6%/year, and the rate of decline was directly related to age but not to sex, measures of adiposity, or serum glucose. Dehydroepiandrosterone sulfate concentrations differed significantly by sex and age group. The average decline in the sulfated hormone was 2.0%/year and was not related to age, sex, measures of adiposity, or serum glucose. Knowledge of the natural course of age-related changes in dehydroepiandrosterone and dehydroepiandrosterone sulfate concentrations is essential to our understanding of the relationship of dehydroepiandrosterone to chronic diseases.

Adult↗
PubMed1998

Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.

OBJECTIVES: This study sought to evaluate long-term predictors of coronary events in men and women with arteriographically defined coronary artery disease (CAD). BACKGROUND: There is conflicting evidence of the role of triglycerides (TGs) as a prognosticator of CAD, and no studies have examined the long-term outcome of "normal" levels in predicting new coronary events. METHODS: This was a retrospective cohort study that evaluated 740 consecutive patients presenting for diagnostic coronary arteriography between 1977 and 1978. Beginning in 1988, patients with arteriographic CAD (n=350) were recontacted and asked to complete detailed medical questionnaires. Case and control patients were stratified by development of new coronary events, including death from ischemic heart disease, nonfatal myocardial infarction and revascularization. RESULTS: There were 199 events during the 18-year follow-up period. The mean high density lipoprotein cholesterol (HDL-C) was significantly lower (35 vs. 39 mg/dl; p=0.002) and TGs higher (160 vs. 137 mg/dl; p=0.03) in case patients than in control patients; After adjusting for age, gender and beta-adrenergic blocking agent use, multiple logistic regression analysis revealed the following independent predictors of CAD events: diabetes mellitus (relative risk [RR] 2.1, 95% confidence interval [CI] 1.4% to 3.1%), HDL-C <35 mg/dl (RR 1.5, 95% CI 1.1% to 2.00) and TGs >100 mg/dl (RR 1.5, 95% CI 1.1% to 2.1%). A Kaplan-Meier analysis revealed significantly reduced survival from CAD events in patients with baseline TG levels > or = 100 mg/dl compared with TG levels <100 mg/dl (p=0.008). CONCLUSIONS: TG levels previously considered "normal" are predictive of new CAD events. The cutpoints established by the National Cholesterol Education Program for elevated TGs (>200 mg/dl) may need to be refined.

Coronary Disease↗
PubMed1998

Successful medical therapy for deeply invasive facial infection due to Pythium insidiosum in a child.

Pythiosis occurs in animals and humans who encounter aquatic habitats that harbor Pythium insidiosum. Drug therapy for deeply invasive infections with this organism has been ineffective in humans and animals; patients have been cured only by radical surgical debridement. A 2-year-old boy developed periorbital cellulitis unresponsive to antibiotic and antifungal therapy. The cellulitis extended to the nasopharynx, compromising the airway and necessitating a gastrostomy for feeding. P. insidiosum was isolated from surgical biopsy specimens of the affected tissue. On the basis of in vitro susceptibility studies of the isolate, the patient was treated with a combination of terbinafine and itraconazole. The infection resolved over a period of a few months. The patient remained well 1.5 years after completing a 1-year course of therapy. Cure of deep P. insidiosum infection is feasible with drug therapy.

Anti-Infective Agents↗
PubMed1998

LDL-cholesterol: a risk factor for coronary artery disease--from epidemiology to clinical trials.

Discussion of potential strategies to modify lipids and lipoproteins other than low density lipoproteins (LDLs) should first recognize the convincing evidence in favour of the identification and aggressive treatment of elevated LDL cholesterol (LDL-C) levels in patients with established cardiovascular disease. Elevated LDL-C level is one of the few risk factors for which there is evidence of involvement in every pathophysiological step of the development of cardiovascular disease. Longitudinal studies have established the role of LDL-C as a risk factor for cardiovascular disease incidence, recurrence and fatal outcome. Clinical trials and economic analyses have proven that aggressive treatment of elevated LDL-C in patients at high risk can prevent cardiac events with excellent cost effectiveness.

Cholesterol, LDL↗
PubMed1997

The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient.

Progress in vascular biology, epidemiology, clinical trials, and cost-effectiveness analyses have allowed development of guidelines for risk reduction in patients with vascular disease and congestive heart failure. However, these advances appear necessary but not sufficient to promote implementation of these guidelines for treating coronary artery disease (CAD) and congestive heart failure (CHF). Evidence from the United Kingdom and Europe, and estimates from the United States, suggest that a large "treatment gap" exists between recommended therapies for patients with cardiovascular disease and the care that they are actually receiving. Despite known interventions with proven efficacy to reduce disease recurrence and death from CAD and CHF, only a minority of patients are receiving any intervention whatsoever. A second problem is that, among those receiving care, many are undertreated resulting in a very small number of patients reaching goals and recommended levels of therapy. Third, the levels of intervention and the proportion of patients at goal that should be attainable (i.e., community standards) are not known. A variety of barriers exist for implementation of preventive cardiology services. Although the patient has a chain of opportunities for risk reduction, it is not clear which of the links in this chain (inpatient/hospital programs, specialist/generalist communication, ambulatory care, or patient compliance) is the major reason for the treatment gap. An ongoing project, the American College of Cardiology Evaluation of Preventive Therapeutics (ACCEPT), will attempt to quantify the treatment gap in coronary disease patients in the United States and will try to identify those barriers playing the greatest role in limiting the optimal care of the coronary disease patient.

Coronary Disease↗